Bon Natural Life (BON) Competitors $1.53 -0.08 (-4.97%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. NMTR, PTPI, TRVN, REVB, HEPA, VIRX, SYRS, ATXI, BIOR, and BPTSYShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Revelation Biosciences (REVB), Hepion Pharmaceuticals (HEPA), Viracta Therapeutics (VIRX), Syros Pharmaceuticals (SYRS), Avenue Therapeutics (ATXI), Biora Therapeutics (BIOR), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors 9 Meters Biopharma Petros Pharmaceuticals Trevena Revelation Biosciences Hepion Pharmaceuticals Viracta Therapeutics Syros Pharmaceuticals Avenue Therapeutics Biora Therapeutics Biophytis Bon Natural Life (NYSE:BON) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking. Is BON or NMTR more profitable? Bon Natural Life's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Bon Natural LifeN/A N/A N/A 9 Meters Biopharma N/A -584.97%-159.45% Which has better earnings & valuation, BON or NMTR? Bon Natural Life has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBon Natural Life$23.84M0.01$400KN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Do institutionals & insiders hold more shares of BON or NMTR? 0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in BON or NMTR? 9 Meters Biopharma received 37 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformBon Natural LifeN/AN/A9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Which has more volatility and risk, BON or NMTR? Bon Natural Life has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Does the media favor BON or NMTR? In the previous week, Bon Natural Life's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment Bon Natural Life Neutral 9 Meters Biopharma Neutral SummaryBon Natural Life beats 9 Meters Biopharma on 5 of the 8 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$256K$1.23B$7.91B$19.68BDividend YieldN/AN/A3.28%3.81%P/E RatioN/A12.7814.9434.98Price / Sales0.0110.323.6542.86Price / Cash0.7810.4016.3717.51Price / Book0.041.444.764.78Net Income$400K-$56.07M$258.55M$1.02B7 Day Performance-7.27%-4.50%1.16%0.82%1 Month Performance2.00%-1.45%1.81%1.74%1 Year Performance-97.37%-34.18%0.07%10.57% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.53-5.0%N/A-97.2%$256K$23.84M0.00100NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PTPIPetros Pharmaceuticals0.389 of 5 stars$0.03-4.8%N/A-99.7%$991K$5.11M-0.0120Short Interest ↑Gap DownTRVNTrevena1.752 of 5 stars$1.02-3.0%$5.00+390.2%-89.8%$978K$443K-0.0240Gap UpREVBRevelation Biosciences0.4332 of 5 stars$0.87+0.7%N/A-97.8%$834KN/A0.0010Short Interest ↑HEPAHepion Pharmaceuticals1.2516 of 5 stars$0.06+10.3%N/A-99.9%$689KN/A-0.0120News CoverageShort Interest ↓VIRXViracta Therapeutics1.9744 of 5 stars$0.02-8.8%$1.75+11,190.3%-97.3%$676KN/A-0.0120Gap DownSYRSSyros Pharmaceuticals3.7048 of 5 stars$0.03-2.0%$3.33+13,233.3%-99.6%$671K$386K-0.01120Gap UpATXIAvenue Therapeutics1.8194 of 5 stars$0.20-22.8%N/A-93.9%$639KN/A0.014Gap DownBIORBiora Therapeutics1.7563 of 5 stars$0.14+3.1%$23.00+16,328.6%-98.1%$633K$892K-0.01120Gap UpBPTSYBiophytisN/A$1.38-20.2%N/A-82.2%$484KN/A0.0030Short Interest ↑ Related Companies and Tools Related Companies 9 Meters Biopharma Competitors Petros Pharmaceuticals Competitors Trevena Competitors Revelation Biosciences Competitors Hepion Pharmaceuticals Competitors Viracta Therapeutics Competitors Syros Pharmaceuticals Competitors Avenue Therapeutics Competitors Biora Therapeutics Competitors Biophytis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
